Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with …

Patients with type 2 diabetes are at high risk for development of cardiovascular disease,
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …

This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …

Background There is a paucity of global data on cardiovascular disease (CVD) prevalence
in people with type 2 diabetes (T2D). The primary objective of the CAPTURE study was to …

Background Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal
outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the …

Background: We assessed the effect of once-weekly semaglutide and once-daily liraglutide
on kidney outcomes in type 2 diabetes. Methods: Pooled (n= 12 637) and by-trial data from …

Nearly half of all adults with type 2 diabetes mellitus (T2DM) live in India and China. These
populations have an underlying predisposition to deficient insulin secretion, which has a key …

Heart failure (HF) has been recognized as a common complication of diabetes, with a
prevalence of up to 22% in individuals with diabetes and increasing incidence rates. Data …

Background: Several pharmacologic options for type 2 diabetes are available. Purpose: To
compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes. Data …

Background Establishing cardiovascular safety of new therapies for type 2 diabetes is
important. Safety data are available for the subcutaneous form of the glucagon-like peptide …